Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

PRostate cancer OMics Oriented inTErvention

Project description

Improving prostate cancer management with AI

Prostate cancer is a relatively common type of cancer, affecting millions of men worldwide each year. Early-stage prostate cancer, which is often slow-growing, typically has a favourable prognosis with high survival rates, especially when detected and treated promptly. However, advanced or metastatic prostate cancer is more difficult to treat and presents with poorer prognosis. With the support of the Marie Skłodowska-Curie Actions programme, the PROMOTE project aims to train doctoral candidates in the use of omics technologies and artificial intelligence (AI) to improve clinical management of prostate cancer patients. The project will develop non-invasive tools using biomarkers and AI to guide treatment decisions and create effective therapies for advanced disease.

Objective

PROMOTE focuses on multidisciplinary education of doctoral candidates (DCs) in -omics and artificial intelligence (AI) mediated intervention to improve clinical management of Prostate Cancer (PCa). PCa is the second most common malignancy, affecting ~1.3 million men every year worldwide. Tragically, there is a treatment paradox, as ~45% of PCa patients experience slow-growing cancer and are unlikely to progress rapidly, while PCa is not curable at advanced stage. Evidently, clinical management of PCa is not optimal, as patients which do not require treatment are over-treated, while for those that immediate actions are required, efficient treatment are still needed.
To fill the above gaps, PROMOTE was formed to educate DCs in emerging -omics and AI technologies and deliver:
a) novel non-invasive tools (based on biomarker- and AI- models) to guide intervention, and
b) more efficient treatment options for advanced PCa (particularly metastatic) driven by molecular characterisation of the disease phenotypes.
PROMOTE brings together 13 leading centers from different disciplines, including 3 SMEs, 4 university hospitals with clinical laboratories and 2 research institutes and 4 universities, closely collaborating with solid scientific background, as demonstrated by multiple publications. PROMOTE research builds on:
i) available biobanks and -omics datasets within PROMOTE consortium, including >3000 urinary proteomics, >1100 imaging datasets paired with biopsy and pathology data, >350 paired RNA and proteomics urinary profiles, >100 tissue proteomics and ~300 phospho, proteo-genomic and transcriptomics profiles from public repositories,
ii) established software and analytical protocols on -omics data integration, AI feature extraction and integration, systems biology, pathway enrichment, drug repurposing and in vitro testing, and
iii) infrastructure to support hosting and training of DCs.
Moreover, PROMOTE training programme has strong innovation and industrial focus.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN-ID - HORIZON TMA MSCA Doctoral Networks - Industrial Doctorates

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-DN-01

See all projects funded under this call

Coordinator

MOSAIQUES DIAGNOSTICS GMBH
Net EU contribution
€ 781 617,60
Address
ROTENBURGER STRASSE 20
30659 Hannover
Germany
SME
Yes
Region
Niedersachsen Hannover Region Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Participants (6)

Partners (8)